Effect of CDCA8 on the prognosis of patients with hepatocellular carcinoma

Zeng Maolin; Xu Ting; He Jinyue; Liu Shengwei; Su Fengjuan

doi:10.13406/j.cnki.cyxb.003164

您当前的位置：

首页 >

文章列表页 >

Effect of CDCA8 on the prognosis of patients with hepatocellular carcinoma

Clinical study | 更新时间：2025-10-21

- Effect of CDCA8 on the prognosis of patients with hepatocellular carcinoma
- Journal of Chongqing Medical University Vol. 48, Issue 2, Pages: 190-194(2023)
- 作者机构：
  
  1.重庆医科大学附属永川医院，药学部，重庆 402160
  2.重庆医科大学附属永川医院，检验科，重庆 402160
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003164
  CLC： R735.7
- Received：07 April 2022，
  
  Revised：2022-05-23，
  
  Accepted：15 June 2022，
  
  Published：28 February 2023
- 稿件说明：
移动端阅览
曾茂林,徐婷,何锦悦,等.CDCA8对肝细胞癌患者预后的影响[J].重庆医科大学学报,2023,48(2):190-194.

Zeng Maolin,Xu Ting,He Jinyue,et al.Effect of CDCA8 on the prognosis of patients with hepatocellular carcinoma[J].Journal of Chongqing Medical University,2023,48(2):190-194.
曾茂林,徐婷,何锦悦,等.CDCA8对肝细胞癌患者预后的影响[J].重庆医科大学学报,2023,48(2):190-194. DOI： 10.13406/j.cnki.cyxb.003164.

Zeng Maolin,Xu Ting,He Jinyue,et al.Effect of CDCA8 on the prognosis of patients with hepatocellular carcinoma[J].Journal of Chongqing Medical University,2023,48(2):190-194. DOI： 10.13406/j.cnki.cyxb.003164.

摘要

目的

肝细胞癌预后相关的分子标志物对提高患者生存质量和改善疗效至关重要，本研究旨在探究细胞分裂周期相关基因8（cell division cycle associated 8，CDCA8）对肝细胞癌预后的影响及潜在分子机制。

方法

432例肝细胞癌样本的转录组数据及对应患者的临床信息下载自肿瘤基因表达图谱（The Cancer Genome Atlas，TCGA）数据库。分析肿瘤组织和正常组织中CDCA8 mRNA差异；根据CDCA8 mRNA中位数将肝细胞癌患者分为高表达组和低表达组，绘制生存曲线。采用Kruskal检验分析CDCA8与肿瘤分期、分级和T分期的相关性。采用单因素和多因素Cox回归分析探究CDCA8能否作为肝细胞癌患者的独立预后因子。采用基因集富集分析（gene set enrichment analysis，GSEA）探究CDCA8在肝细胞癌中的潜在作用机制。

结果

CDCA8在肿瘤组织中的mRNA水平明显高于正常对照组织（

0.001），CDCA8高表达患者的生存率明显低于低表达组（

0.001）。随着肿瘤分期（

0.001）、分级（

0.001）和T分期（

0.001）增加，肝细胞癌恶性程度增加，同时伴随CDCA8 mRNA水平增加。GSEA富集分析发现CDCA8高表达明显富集的通路包括细胞周期和有丝分裂。

结论

CDCA8可作为肝细胞癌患者的预后分子标志物，深入研究后有望成为治疗的新靶点。

Abstract

Objective

Molecular markers related to the prognosis of hepatocellular carcinoma are essential for improving the quality of life of patients and improving the therapeutic efficacy. This study aims to investigate the effect of cell division cycle associated 8 （CDCA8） on the prognosis of hepatocellular carcinoma and its potential molecular mechanism.

Methods

The transcriptome data of 432 cases of hepatocellular carcinoma and the clinical information of the corresponding patients were downloaded from The Cancer Genome Atlas （TCGA） database. The differences of CDCA8 mRNA in tumor tissues and normal tissues were analyzed. The patients with hepatocellular carcinoma were divided into high expression group and low expression group according to the median CDCA8 mRNA，and the survival curve was drawn. Kruskal test was used to analyze the correlation between CDCA8 and tumor stage，grade and T stage. Univariate and multivariate Cox regression analysis were used to investigate whether CDCA8 could be used as an independent prognostic factor for patients with hepatocellular carcinoma. The potential molecular mechanism of CDCA8 in hepatocellular carcinoma was explored using gene set enrichment analysis （GSEA）.

Results

The mRNA level of CDCA8 in tumor tissues was significantly higher than that in control tissues （

0.001），and the survival rate of patients with high CDCA8 expression was significantly lower than that of those with low expression （

0.001）. As tumor stage （

0.001），grade （

0.001） and T stage （

0.001） increase

，the degree of malignancy of hepatocellular carcinoma increases，accompanied by an increase of the mRNA level of CDCA8. GSEA revealed significant pathways for CDCA8 overexpression including cell cycle and mitosis.

Conclusion

CDCA8 can be used as a prognostic molecular marker for patients with hepatocellular carcinoma，and it is expected to become a new target after in-depth study.

关键词

Keywords

references

Chen WQ ， Zheng RS ， Baade PD ， et al . Cancer statistics in China，2015 [J ] . CA A Cancer J Clin ， 2016 ， 66 （ 2 ）： 115 - 132 .

Pomfret EA ， Washburn K ， Wald C ， et al . Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States [J ] . Liver Transpl ， 2010 ， 16 （ 3 ）： 262 - 278 .

He RQ ， Gao L ， Ma J ， et al . The essential role of MTDH in the progression of HCC：a study with immunohistochemistry，TCGA，meta-analysis and in vitro investigation [J ] . Am J Transl Res ， 2017 ， 9 （ 4 ）： 1561 - 1579 .

Zhang X ， Ye ZH ， Liang HW ， et al . Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study [J ] . FEBS Open Bio ， 2017 ， 7 （ 4 ）： 504 - 521 .

Hou YC ， Yu Z ， Tam NL ， et al . Exosome-related lncRNAs as predictors of HCC patient survival：a prognostic model [J ] . Am J Transl Res ， 2018 ， 10 （ 6 ）： 1648 - 1662 .

Wan Z ， Zhang XH ， Luo YY ， et al . Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses [J ] . Genet Test Mol Biomarkers ， 2019 ， 23 （ 11 ）： 766 - 777 .

Yan HX ， Li ZH ， Shen Q ， et al . Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence [J ] . Pathol Res Pract ， 2017 ， 213 （ 4 ）： 316 - 321 .

Li B ， Pu K ， Wu X . Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis [J ] . J Cell Biochem ， 2019 ： 2019Feb11 .

Carmena M ， Wheelock M ， Funabiki H ， et al . The chromosomal passenger complex （CPC）：from easy rider to the godfather of mitosis [J ] . Nat Rev Mol Cell Biol ， 2012 ， 13 （ 12 ）： 789 - 803 .

van der Horst A ， Lens SMA . Cell division：control of the chromosomal passenger complex in time and space [J ] . Chromosoma ， 2014 ， 123 （ 1/2 ）： 25 - 42 .

Bu YH ， Shi LB ， Yu DH ， et al . CDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells [J ] . Gene ， 2019 ， 703 ： 1 - 6 .

Yu DH ， Shi LB ， Bu YH ， et al . Cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer [J ] . J Breast Cancer ， 2019 ， 22 （ 2 ）： 237 - 247 .

Ci C ， Tang B ， Lyu DL ， et al . Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis [J ] . Int J Mol Med ， 2019 ， 43 （ 1 ）： 404 - 412 .

Bi YQ ， Chen S ， Jiang JZ ， et al . CDCA8 expression and its clinical relevance in patients with bladder cancer [J ] . Medicine ， 2018 ， 97 （ 34 ）： e11899 .

Gao X ， Wen XH ， He HW ， et al . Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells [J ] . PeerJ ， 2020 ， 8 ： e9078 .

Qi GH ， Zhang CY ， Ma HL ， et al . CDCA8，targeted by MYBL2，promotes malignant progression and olaparib insensitivity in ovarian cancer [J ] . Am J Cancer Res ， 2021 ， 11 （ 2 ）： 389 - 415 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in yttrium-90 microsphere selective internal radiation therapy in treatment of hepatocellular carcinoma

Effect of DExH-box helicase 9 O-GlcNAc modification on the proliferation of HBV-associated hepatoma cells

Effect of GluA1 interacting proteins GNAI2 and SRSF10 on prognosis of Hepatocellular carcinoma and establishment of diagnostic model

Research progress on the role of SOCS-3 in liver diseases

MRI radiomics combined with clinical indices and LI-RADS features for predicting tumor response after transarterial chemoembolization in patients with intermediate and advanced hepatocellular carcinoma

Related Author

Zhao Yongle

Chen Honglin

Zhang Han

Zhu Xinyue

Yang Zhicheng

Tan Maoting

Zhao Hongyun

Luo Huimin

Related Institution

Department of Gastroenterology，The Second Affiliated Hospital of Chongqing Medical University

Key Laboratory of Molecular Biology on Infectious Diseases， Ministry of Education，Chongqing Medical University

Department of Biochemistry and Molecular Biology，School of Basic Medicine，Chongqing Medical University

Department of Pathology, The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University

Department of Infectious Diseases and Liver Diseases, The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University

⁰